We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Merck & Co Inc | LSE:0QAH | London | Ordinary Share | MERCK & CO ORD (CDI) |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
126.60 | 133.40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 60.12B | 365M | 0.1440 | 899.44 | 328.21B |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
18:37:53 | O | 600 | 129.40 | USD |
Date | Time | Source | Headline |
---|---|---|---|
25/4/2024 | 12:13 | ALNC | Merck & Co raises annual outlook thanks to first quarter boost |
15/3/2024 | 15:23 | ALNC | IN BRIEF: Merck hails positive data on cervical cancer drug, Keytruda |
20/2/2024 | 21:15 | ALNC | Merck and Astellas drugs get priority review in US and Japan |
01/2/2024 | 12:57 | ALNC | TOP NEWS: Merck books 2023 growth despite gefapixant rejection hit |
19/1/2024 | 11:29 | ALNC | IN BRIEF: Arix Bioscience eyes USD19 million return from Harpoon sale |
08/1/2024 | 14:20 | ALNC | Merck to buy Harpoon Therapeutics for about USD680 million |
18/12/2023 | 11:04 | ALNC | Astellas, Merck, Pfizer celebrate US approval for Keytruda plus Padcev |
15/12/2023 | 08:41 | ALNC | Merck gets US FDA nod for Welireg, as trial with Moderna bears fruit |
11/12/2023 | 17:56 | ALNC | Merck reports mixed updates for cancer treatment, Keytruda |
26/10/2023 | 12:17 | ALNC | TOP NEWS: Merck hails Daiichi Sankyo partnership but will take charge |
Merck & (0QAH) Share Charts1 Year Merck & Chart |
|
1 Month Merck & Chart |
Intraday Merck & Chart |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
18:12:16 | 129.51 | 16 | 0.00 | O |
17:37:53 | 129.40 | 600 | 0.00 | O |
17:34:05 | 129.47 | 3 | 0.00 | O |
17:33:09 | 129.50 | 2,200 | 0.00 | O |
17:14:53 | 129.77 | 24 | 0.00 | O |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions